AirNexis Therapeutics
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
AirNexis Therapeutics Launches with $200M Series A
AirNexis Therapeutics has emerged from stealth with $200 million in Series A financing to advance a novel therapy for chronic obstructive pulmonary disease (COPD).
The round was led by Frazier Life Sciences with participation from OrbiMed, SR One, Goldman Sachs, Longitude Capital, and Enavate Sciences.
Key Highlights
- One of the largest Series A rounds in biotech
- Novel dual PDE3/4 inhibitor for COPD
- Combines bronchodilation and inflammation reduction
Company Overview
AirNexis Therapeutics is developing a dual PDE3/4 inhibitor that combines bronchodilation with anti-inflammatory effects, potentially offering COPD patients a more effective treatment option.
Company Info
Investors (4)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
Terra Industries Raises $11.75M Seed | African Defense Tech
African defense technology startup Terra Industries secures $11.75 million seed funding led by 8VC for autonomous surveillance.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free